Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?-Reference-Cited by-同舟云学术

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Published:2020-10-19 Issue:6 Volume:35 Page:1571-1585
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Martínez-Cuadrón David^ORCID,Serrano Josefina,Gil Cristina,Tormo Mar,Martínez-Sánchez Pilar,Pérez-Simón José A.,García-Boyero Raimundo,Rodríguez-Medina Carlos,López-Pavía María,Benavente Celina,Bergua Juan^ORCID,Lavilla-Rubira Esperanza^ORCID,Amigo María L.^ORCID,Herrera Pilar,Alonso-Domínguez Juan M.^ORCID,Bernal Teresa^ORCID,Colorado Mercedes,Sayas María J.,Algarra Lorenzo,Vidriales María B.^ORCID,Rodríguez-Macías Gabriela,Vives Susana,Pérez-Encinas Manuel M.^ORCID,López Aurelio,Noriega Víctor,García-Fortes María,Ramos Fernando^ORCID,Rodríguez-Gutiérrez Juan I.,Costilla-Barriga Lisette,Labrador Jorge,Boluda Blanca,Rodríguez-Veiga Rebeca^ORCID,Martínez-López Joaquín^ORCID,Sanz Miguel A.^ORCID,Montesinos Pau^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-020-01058-4.pdf

Reference44 articles.

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

2. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019. https://doi.org/10.6004/jnccn.2019.0028.

3. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.

4. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137–45.

5. DiNardo CD, Stein EM, De Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386–98.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of action of 1,4-naphthoquinone scaffold-derived compounds against acute myeloid leukemia based on network pharmacology, molecular docking and molecular dynamics simulation;Scientific Reports;2024-09-09

2. CSRP1 gene: a potential novel prognostic marker in acute myeloid leukemia with implications for immune response;Discover Oncology;2024-06-27

3. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry;Cancer;2024-06-19

4. Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines;2024-02-27

5. A nomogram based on clinical features and molecular abnormalities for predicting the prognosis of patients with acute myeloid leukemia;Translational Cancer Research;2023-12